Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified platelet-rich plasma + somatotropin + Strophanthus kombe is an investigational regenerative biologic combination therapy. It is a key component of the Nanosurgery and Bioengineered Regenerative Treatment (NSBT) protocol developed by the Wasilczyk Medical Clinic in Poland. The combination consists of autologous platelet-rich plasma (PRP) enriched with somatotropin (human growth hormone) and a botanical extract from *Strophanthus kombe*, which serves as a source of cardiac glycosides. This mixture is administered via ultrasound-guided injection to promote tissue repair and regeneration in musculoskeletal conditions such as lumbar disc herniation and hip osteoarthritis. The mechanism of action involves growth factor signaling from PRP and somatotropin, alongside potential cellular modulation by cardiac glycosides.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified platelet-rich plasma + somatotropin + Strophanthus kombe.